Arlington Capital Partners Acquires Riverpoint Medical to Advance Bioactive Textile-Based Surgical Solutions

On August 16, 2019, VCBeat (WeChat ID: vcbeat) learned from foreign media reports that U.S. venture capital firm Arlington Capital Partners (Arlington) announced the acquisition of medical device company Riverpoint Medical (Riverpoint). No financial terms of the transaction were disclosed.

Riverpoint, founded by the Ferguson family in 2008 and headquartered in Portland, Oregon, USA, is a specialized medical device company. Its Vice President of Marketing, Wayne Black, possesses expertise in medical device research and development. The company holds intellectual property rights for products such as high-strength medical sutures, primarily manufactures biomedical textile materials, and designs, develops, and markets novel surgical medical devices. Riverpoint’s advanced medical devices meet market demands in areas including surgical suturing, sports medicine, animal health, and regenerative medicine.

Riverpoint manufactures bioabsorbable and non-absorbable sutures, primarily used in surgical procedures such as wound closure. The company also provides wireless LED surgical headlamps (MedLED) and endocavitary brachytherapy products for the oncology market. These brachytherapy products deliver radioactive sources into the patient’s body to treat cancer, and are mainly indicated for superficial primary tumors, residual tumors following external beam radiation therapy, and endocavitary tumors.

In addition, Riverpoint has designed and developed HSFiber, a world-renowned material widely used in sports medicine products. Leveraging this material, the company manufactures a range of sports medicine products, including high-strength sutures, suture tapes, and annulus fibrosus devices, all of which have received high acclaim from the surgical medical community. Riverpoint seeks to collaborate with surgeons to jointly improve patient outcomes.

Arlington, established in 1999, is a venture capital and private equity firm headquartered in Washington, D.C., United States. The firm manages five investment funds with total assets under management exceeding $4 billion. Arlington boasts an experienced investment management team that focuses on growth-oriented sectors, including healthcare, innovative technologies, aerospace, and software development. Since its inception, the company has completed more than 90 acquisitions.

Matt Altman, Managing Partner at Arlington, stated, “We are delighted to partner with the Riverpoint team to continue developing innovative surgical medical devices. Riverpoint’s advanced manufacturing technologies streamline the production process for medical devices, aligning with the evolving demands of the healthcare market. This acquisition reinforces Arlington’s enduring mission to build differentiated, high-growth medical device manufacturers through strategic partnerships.”

Riverpoint CEO Pat Ferguson stated, “Riverpoint chose to partner with Arlington due to its impressive track record in scaling medical device manufacturing companies. We believe this acquisition will enable Riverpoint to achieve technological advancements and significant business growth, delivering high-quality medical devices to surgeons and patients.”

(Compiled by Xu Xiaoxue)